SCHEMBL4828602

SCHEMBL4828602

CN(C)S(=O)(=O)n1cnc(C(O)c2cccs2)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 4/20 0.37
TDO2 P48775 4/20 0.37
TSHR P16473 2/20 0.35
MAPT P10636 3/20 0.35
HSD17B10 Q99714 1/20 0.35
HTT P42858 3/20 0.34
TOP2A P11388 2/20 0.33
TOP2B Q02880 2/20 0.33
ALOX5 P09917 1/20 0.33
NPC1 O15118 1/20 0.32
RAB9A P51151 1/20 0.32
CES2 O00748 1/20 0.32
CES1 P23141 1/20 0.32
KEAP1 Q14145 1/20 0.32
EGFR P00533 1/20 0.32
PGR P06401 1/20 0.31
ALDH1A1 P00352 2/20 0.31
PKM P14618 1/20 0.31
HPGD P15428 1/20 0.31
ATM Q13315 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31531675 0.75 HTT (0.40) TSHRHTTNPSR1GAA
SCHEMBL31040271 0.74 HTT (0.36) HTTALDH1A1
SCHEMBL6430024 0.73 IDO1 (0.45) IDO1TDO2TSHRMAPTHSD17B10
SCHEMBL3747956 0.73 UGT2B7 (0.39) TSHRATM
SCHEMBL31531686 0.72 ADRA2A (0.50) NPC1RAB9AEGFR
SCHEMBL9876151 0.72 HTT (0.36) HTTALDH1A1GAA
SCHEMBL4825746 0.72 ALDH1A1 (0.41) TSHRHSD17B10HTTALDH1A1PKM
SCHEMBL4828770 0.71 MAPT (0.31) IDO1TDO2TSHRMAPTHSD17B10
SCHEMBL31040273 0.71 CA12 (0.42) TSHRMAPTHTTNPC1ALDH1A1
SCHEMBL9951819 0.70 HTT (0.41) TSHRHTTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080221152-A1 4-(HETEROARYL-METHYL AND SUBSTITUTED HETEROARYL-METHYL)-IMIDAZOLE-2-THIONES ACTING AS ALPHA2 ADRENERGIC AGONISTS ALLERGAN, INC. (US) 2008-09-11 US disclosed
US-7399868-B2 4-(Heteroaryl-methyl and substituted heteroaryl-methyl)-imidazole-2-thiones acting as alpha2 adrenergic agonists ALLERGAN, INC. (US) 2008-07-15 US disclosed
EP-1791832-A1 4-(HETEROARYL-METHYL AND SUBSTITUTED HETEROARYL-METHYL)-IMIDAZOLE-2-THIONES ACTING AS ALPHA2 ADRENERGIC AGONISTS Allergan, Inc. (US) 2007-06-06 EP disclosed
WO-2006036507-A1 4-(HETEROARYL-METHYL AND SUBSTITUTED HETEROARYL-METHYL)-IMIDAZOLE-2-THIONES ACTING AS ALPHA2 ADRENERGIC AGONISTS ALLERGAN, INC. (US) 2006-04-06 WO disclosed
US-20060069143-A1 4-(Heteroaryl-methyl and substituted heteroaryl-methyl)-imidazole-2-thiones acting as alpha2 adrenergic agonists ALLERGAN, INC. 2006-03-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080221152-A1 4-(HETEROARYL-METHYL AND SUBSTITUTED HETEROARYL-METHYL)-IMIDAZOLE-2-THIONES ACTING AS ALPHA2 ADRENERGIC AGONISTS ADRB2, ADRA2C, ADRA2A IDO1 1408/4885TDO2 1065/4885TSHR 345/4885
US-20060069143-A1 4-(Heteroaryl-methyl and substituted heteroaryl-methyl)-imidazole-2-thiones acting as alpha2 adrenergic agonists ADRB2, ADRA2C, ADRA2A IDO1 1678/4885TDO2 1184/4885TSHR 461/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.